Chicarelli, Mark J.
Array BioPharma (United States)
3 papers on CoChat
Most cited papers
- Verified
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry
Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity
Cited by 653
- Verified
Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity
Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters
Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity
Cited by 120
- Verified
Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer
Marx, M. A., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Briere, D. M., Burgess, L. E., Burkhard, M. R., Chiang, H., Chicarelli, M. J., et al. (2020) · Molecular Cancer Research
Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free